


AMENDMENTS TO THE CLAIMS

1. - 7. (Canceled)

8. (Currently Amended) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound



wherein

R⁴ is lower alkanoyl,

R⁷ is phenyl substituted with halogen,

Z is a single bond,

J is -NH-, and

Q is -CO-,

or pharmaceutically acceptable salts thereof.

9. - 12. (Canceled)

13. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 8, which is a method for the prophylaxis or treatment of one or more cerebral diseases.

14. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 13, wherein said cerebral disease is dementia or amnesia.

15. - 30. (Canceled)


→ 31. (Currently Amended) A method for screening an agent for expression of long-term potentiation of synaptic transmission, which comprises stimulating hippocampal slices,

112 enablement

in vitro comp

OK
in vitro
data with double
to support
in vitro
mechanism is what you're trying to prove
OK

bringing a hippocampal slice into contact with a test compound having the following formula:



wherein

R^4 is lower alkanoyl,

R^7 is phenyl substituted with halogen,

Z is a single bond,

J is $-NH-$, and

Q is $-CO-$,

or pharmaceutically acceptable salts thereof,

measuring an amount of somatostatin released from the hippocampal slice and/or a release time thereof, measuring an amount of somatostatin released from a hippocampal slice and/or a release time thereof in the absence of a contact with the test compound, and comparing the amounts and/or the times to calculate the amount of somatostatin released from the hippocampal slice and/or the release time thereof caused by the contact with the test compound.

→ 32. (Original) The screening method according to claim 31, which is a screening method of an anti-dementia agent or anti-amnesia agent. ⇒ in vivo

33. (Canceled)

34. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound obtained by the screening method of claim 31.

35. (Canceled)

36. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission which comprises a compound obtained by the screening method of claim 31 and a pharmaceutically acceptable carrier or excipient.

37. (Canceled)

38. (Previously Presented) A compound selected by the screening method of claim 31.

39. – 55. (Canceled)

56. (Previously Presented) The method of claim 8, wherein said compound is N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide.